Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes (DIABIL-2)
Type 1 Diabetes
About this trial
This is an interventional treatment trial for Type 1 Diabetes focused on measuring IL2, Interleukin 2, IL-2, Auto-immune disease, Insulin, Diabetes, Regulatory T cells, Treg, Immunoregulation, Immune tolerance, Immunotherapy
Eligibility Criteria
Inclusion criteria
- Age 6-35 years old.
- Male or female both using effective methods of contraception during treatment if sexually active.
- Specifically; Females (if sexually active) with childbearing potential must use contraceptive methods that are considered as highly-effective (pearl index < 1). The following methods are acceptable: Oral , injectable, or implanted hormonal contraceptives (with the exception of oral minipills ie low-dose gestagens which are not acceptable (lynestrenol and norestisteron), Intrauterine device, Intrauterine system (for example, progestin-releasing toit),
- beta HCG negative at inclusion;
- With type-1 diabetes:
- Newly diagnosed (ADA criteria, see annexe 19.6) at most three months between insulin initiation and anticipated start of experimental treatment.
- Positive for one or more of the autoantibodies typically associated with T1D (anti-islet, -insulin, -GAD, -IA2, -ZnT8)
- With a detectable peak C-peptide concentration during a standardised MMTT at Visit MMTT (≥0.2pmol/ml);
- patients with a stable blood glucose level and seric glycaemia between 60 mg/dL and 250 mg/dL verified at MMTT visit
- Absence of clinically significant abnormal laboratory values (out of range and associated with clinical symptoms or signs) in haematology, biochemistry, thyroid, liver and kidney function;
- Normal cardiac function: no documented history of heart disease and absence of family history of sudden death, normal ECG especially QTc duration within normal value (<480ms);
- Free, informed and written consent, signed by the patient and investigator before any Study examination. If the patient is a minor by child and both parents or child and the legal representative in case only one parent is alive. (Journal officiel des communautés européennes (1.5.2001)
- NB: patient with history of thyroidism on treatment at the inclusion and with normal thyroid hormone values (TSH+T4) can be included.
Exclusion criteria
- Children under the age of 6 years old cannot be included
- Patient who, before inclusion, have been treated with other anti-diabetic medication than Insulin for more than 3 months consecutively
- Chronic adrenal insufficiency known or fasting ACTH ≥2.5 ULN normal at inclusion after control;
- Anti TPO present at inclusion and abnormal TSH and T4
- Anti-transglutaminase positive at inclusion
- Hypersensitivity to the active substance or to any of the excipients
- Any major health problem including: any major auto-immune/auto-inflammatory disease (other than type 1 diabetes) present at inclusion, any significant respiratory disease (such as moderate or severe COPD or asthma) requiring the chronic use of corticosteroids (whatever route of administration) and serious digestive malfunctions.
- Patient with existing malignancy or history of malignancy
- Major psychosocial instability with expected lack of compliance with insulin treatment, psychiatric pathology of patient or parents, or major problems of family dynamics;
- Signs of active infection;
- Any patient with obesity defined as BMI ≥ 35
- Existence of a serious malfunction of a vital organ;
- History of organ allograft;
- Use of treatments not allowed in the Study (see Section 8.4.2);
- Vaccination with alive attenuated virus within 4 weeks of the first injection of the induction period and during the whole maintenance period
- Pregnant female (confirmed by laboratory testing) or lactating
- Participation in another clinical trial in the previous 3 months;
- Lack of affiliation to a social security scheme (as a beneficiary or assignee).
Sites / Locations
- Pediatric Department, Centre Hospitalier Régional de la Citadelle
- UZ - Diabetes voor Kinderen en Adolescenten-Leuven
- CHU UCL Namur - site Godinne
- Centre d'Investigations Cliniques, CHU-HOPITAL HAUTEPIERRE
- Centre d'Investigations Cliniques, HÔPITAL CIVIL
- Service de pédiatrie 1CHU de HAUTEPIERRE
- Structure d'Endocrinologie-Diabète-Nutrition et Addictologie HOPITAUX UNIVERSITAIRES NHC
- Service d'endocrinologie, diabétologie, maladies métaboliques, et nutrition, CHU de Bordeaux, Hôpital Haut Levêque
- Service d' Endocrinologie HOPITAL CAVALE BLANCHE
- Service de Pédiatrie, HOPITAL MORVAN
- Service de Pédiatrie CHRU DE NANTES
- Service d' Endocrinologie Diabétologie CHRU DE RENNES
- Médecine pédiatrique, CHU Jean Minjoz
- Service Diabétologie -Endocrinologie, CHU Jean Minjoz
- CIC Paris-Est (Adultes), Hôpitaux Universitaires Pitié-Salpêtrière, Charles Foix
- CIC pédiatrique Hôpital Necker Enfants Malades
- Endocrinologie gynécologie diabétologie pédiatriques, Hôpital Universitaire Necker Enfants Malades.
- CIC Pédiatrique, Hôpital d'enfants Robert Debré
- Institut E3M, Hôpital Pitié-Salpêtrière
- Service d'Endocrinologie Pédiatrique, Hôpital d'enfants Robert Debré
- Service Pédiatrie - Gastro-entérologie, Hépatologie, Nutrition, Diabétologie, Hôpital des Enfants Pôle Enfants
- CHRU de Lille, Hôpital Claude Huriez Service d'endocrinologie
- Service d' Endocrinologie, maladies métaboliques HOPITAL NORD
- Service de Nutrition - Maladies Métaboliques - Endocrinologie HOPITAL DE LA CONCEPTION
- Hopital G&R Laënnec , Endocrinologie, Maladies Métaboliques et Nutrition
- Unité d'Endocrinologie et Diabétologie Pédiatriques, CHU de Marseille, Hôpital La Timone Enfants
- Endocrinologie-Diabétologie-Maladies de la nutrition, Centre Hospitalier Lyon-Sud
- Service d'Endocrinologie pédiatrique - HFME
- Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg
- Division of Endocrinology, Diabetology and Metabolic Diseases, University Hospital of Freiburg, Department for children and adolescents
- Institute of Diabetes Research, Helmholtz Zentrum München
- Center for Pediatric and Adolescent Diabetes Care and Research
- Dept. of Clinical Sciences Lund University, Skåne University Hospital.
- Endocrinology and Diabetes department, University Hospital of Basel
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
rhIL-2
Placebo
0.5 MIU/m²/day of IL2 with a maximum of 1MIU/day in a volume of 1 ml for children and adolescents, 1MIU/day for adults. Subcutaneous injection every day (5 days) then: Regimen A injection every two weeks between D15 and D351, Regimen B injections every week between D15 and D351
Placebo with a identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 days) then: Regimen A injection every two weeks between D15 and D351 Regimen B injections every week between D15 and D351